Comparable stake leader
NIOWAVE, INC.
SEC ownership of Aptevo Therapeutics Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001671584.
Disclosed value leader
YA II PN, Ltd.
Comparable rows
27/28
Latest evidence
06 Aug 2026
- Public ticker
- APVO on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
NIOWAVE, INC.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
27 of 28
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
NIOWAVE, INC.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
06 Aug 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001671584
- Issuer location
- Seattle, WA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Aptevo Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
NIOWAVE, INC.
Disclosed value leader
YA II PN, Ltd.
Comparable rows
27/28
Latest evidence
06 Aug 2026
13D/G
3/4/5
13F
Lead comparable stake: 12%
1 rows are not safely comparable across share classes.
13D/G row: NIOWAVE, INC.
Showing 1-8 of 28 holder rows.
Quick read
NIOWAVE, INC. leads the comparable SEC ownership view at 12%.
27 of 28 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens NIOWAVE, INC.'s linked filing trail.
Comparable ownership
Top 5
NIOWAVE, INC.
12%
Ayrton Capital LLC
10%
YA II PN, Ltd.
10%
BIGGER CAPITAL FUND L P
10%
CVI Investments, Inc.
6.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 28 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| NIOWAVE, INC. |
13D/G
3/4/5
10%+ Owner
|
12%
|
$757,098
151,723 shares
|
$0 | 25 May 2026 |
| Ayrton Capital LLC |
13D/G
|
10%
|
$107,445
358,150 shares
|
$0 | 30 Jun 2025 |
| YA II PN, Ltd. |
13D/G
|
10%
|
$1,663,965
357,842 shares
|
$0 | 16 Jun 2025 |
| BIGGER CAPITAL FUND L P |
13D/G
|
10%
|
—
285,000 shares
|
$0 | 18 Jun 2025 |
| CVI Investments, Inc. |
13D/G
|
6.3%
|
$347,994
83,854 shares
|
$0 | 30 Jun 2026 |
| L1 Capital Global Opportunities Master Fund, Ltd. |
13D/G
|
5%
|
$492,900
164,300 shares
|
-$362,100 | 14 Aug 2025 |
| Hudson Bay Capital Management LP |
13D/G
|
5%
|
$52,853
76,598 shares
|
$0 | 31 Dec 2024 |
| BANK OF AMERICA CORP /DE/ |
13D/G
3/4/5
10%+ Owner
|
0%
|
$125
86 shares
|
-$715,879 | 31 Oct 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$20,134.
Buys
$20,134
Insiders: 1
Sells
$0
Insiders: 0
Net
+$20,134
Shares: +13,513
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 13,513
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 13,513 | 0 | $20,134 | $0 | +$20,134 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Aptevo Therapeutics Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
NIOWAVE, INC.
Net 12M change
+$20,134
Latest report
06 Aug 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| NIOWAVE, INC. | 10%+ Owner | $491,624 | Mixed | 25 May 2026 | ||
| Marvin L. White | Executive Chair, Director | $5,609 | Median | 17 Jul 2026 | ||
| Grady Grant III | Director | $5,116 | +$20,134 | +394% | Median | 06 Aug 2026 |
| Jeffrey G. Lamothe | President and CEO, Director | $4,275 | Median | 06 Aug 2026 | ||
| Daphne Taylor | Svp, Cfo | $2,838 | Median | 06 Aug 2026 | ||
| SoYoung Kwon | SVP, GC, BD & Corp Affairs | $2,838 | Median | 06 Aug 2026 | ||
| Dirk Huebner | Svp, Cmo | $2,144 | Median | 06 Aug 2026 | ||
| Barbara Lopez Kunz | Director | $1,779 | Median | 06 Aug 2026 | ||
| Zsolt Harsanyi | Director | $1,779 | Median | 06 Aug 2026 | ||
| Daniel Abdun-Nabi | Director | $1,779 | Median | 06 Aug 2026 | ||
| John Niederhuber | Director | $1,779 | Median | 06 Aug 2026 | ||
| BANK OF AMERICA CORP /DE/ | 10%+ Owner | $82 | Mixed | 01 Oct 2025 | ||
| Mary Jo Janatpour | Svp, Cso | $0 | Mixed | 20 May 2026 | ||
| Fuad El-Hibri | Director | Mixed | 03 Dec 2021 | |||
| Kevin Tang | Exit Filing | Mixed | 23 Nov 2021 |
Recent insider transactions for Aptevo Therapeutics Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Grady Grant III | APVO | Common Stock | Options Exercise | 53.3% | 400 | 1,150 | 06 Aug 2026 | Direct | ||
| Grady Grant III | APVO | Restricted Stock Unit | Options Exercise | -100% | -400 | 0 | 06 Aug 2026 | Direct | ||
| Barbara Lopez Kunz | APVO | Common Stock | Options Exercise | 400 | 400 | 06 Aug 2026 | Direct | |||
| Barbara Lopez Kunz | APVO | Restricted Stock Unit | Options Exercise | -100% | -400 | 0 | 06 Aug 2026 | Direct | ||
| Jeffrey G. Lamothe | APVO | Common Stock | Options Exercise | 961 | 961 | 06 Aug 2026 | Direct | |||
| Jeffrey G. Lamothe | APVO | Restricted Stock Unit | Options Exercise | -100% | -961 | 0 | 06 Aug 2026 | Direct | ||
| SoYoung Kwon | APVO | Common Stock | Options Exercise | 638 | 638 | 06 Aug 2026 | Direct | |||
| SoYoung Kwon | APVO | Restricted Stock Unit | Options Exercise | -100% | -638 | 0 | 06 Aug 2026 | Direct | ||
| Dirk Huebner | APVO | Common Stock | Tax liability | -24.4% | -156 | 482 | 06 Aug 2026 | Direct | ||
| Dirk Huebner | APVO | Common Stock | Options Exercise | 638 | 638 | 06 Aug 2026 | Direct | |||
| Dirk Huebner | APVO | Restricted Stock Unit | Options Exercise | -100% | -638 | 0 | 06 Aug 2026 | Direct | ||
| John Niederhuber | APVO | Common Stock | Options Exercise | 400 | 400 | 06 Aug 2026 | Direct | |||
| John Niederhuber | APVO | Restricted Stock Unit | Options Exercise | -100% | -400 | 0 | 06 Aug 2026 | Direct | ||
| Marvin L. White | APVO | Common Stock | Tax liability | -24.4% | -406 | 1,261 | 06 Aug 2026 | Direct | ||
| Marvin L. White | APVO | Common Stock | Options Exercise | 166600% | 1,666 | 1,667 | 06 Aug 2026 | Direct | ||
| Marvin L. White | APVO | Restricted Stock Unit | Options Exercise | -100% | -1,666 | 0 | 06 Aug 2026 | Direct | ||
| Daphne Taylor | APVO | Common Stock | Options Exercise | 638 | 638 | 06 Aug 2026 | Direct | |||
| Daphne Taylor | APVO | Restricted Stock Unit | Options Exercise | -100% | -638 | 0 | 06 Aug 2026 | Direct | ||
| Daniel Abdun-Nabi | APVO | Common Stock | Options Exercise | 400 | 400 | 06 Aug 2026 | Direct | |||
| Daniel Abdun-Nabi | APVO | Restricted Stock Unit | Options Exercise | -100% | -400 | 0 | 06 Aug 2026 | Direct | ||
| Zsolt Harsanyi | APVO | Common Stock | Options Exercise | 400 | 400 | 06 Aug 2026 | Direct | |||
| Zsolt Harsanyi | APVO | Restricted Stock Unit | Options Exercise | -100% | -400 | 0 | 06 Aug 2026 | Direct | ||
| Marvin L. White | APVO | Common Stock | Options Exercise | 1 | 1 | 17 Jul 2026 | Direct | |||
| Marvin L. White | APVO | Restricted Stock Unit | Options Exercise | -100% | -1 | 0 | 17 Jul 2026 | Direct | ||
| Grady Grant III | APVO | Common Stock | Purchase | 1351300% | $20,134 | $1.49 | 13,513 | 13,514 | 10 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.